GLP-1 based therapies: clinical implications for gastroenterologists

被引：50

作者：

Smits, Mark M. ^{[1
]}

van Raalte, Daniel H. ^{[1
]}

Tonneijck, Lennart ^{[1
]}

Muskiet, Marcel H. A. ^{[1
]}

Kramer, Mark H. H. ^{[1
]}

Cahen, Djuna L. ^{[2
]}

机构：

[1] Vrije Univ Amsterdam, Med Ctr, Ctr Diabet, Dept Internal Med, De Boelelaan 1117, NL-1081 HV Rotterdam, Netherlands

[2] Erasmus Univ, Med Ctr, Dept Gastroenterol & Hepatol, Rotterdam, Netherlands

来源：

GUT | 2016年 / 65卷 / 04期

关键词：

GLUCAGON-LIKE PEPTIDE-1; DIPEPTIDYL PEPTIDASE-4 INHIBITOR; FATTY LIVER-DISEASE; GASTRIC-ACID-SECRETION; HEALTHY-SUBJECTS; ACUTE-PANCREATITIS; DIABETES-MELLITUS; RECEPTOR AGONIST; EXOCRINE PANCREAS; POSTPRANDIAL GLYCEMIA;

D O I：

10.1136/gutjnl-2015-310572

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

100201 [内科学];

摘要：

The gut-derived incretin hormone, glucagon-like peptide 1 (GLP-1) lowers postprandial blood glucose levels by stimulating insulin and inhibiting glucagon secretion. Two novel antihyperglycaemic drug classes augment these effects; GLP-1 receptor agonists and inhibitors of the GLP-1 degrading enzyme dipeptidyl peptidase 4. These so called GLP-1 based or incretin based drugs are increasingly used to treat type 2 diabetes, because of a low risk of hypoglycaemia and favourable effect on body weight, blood pressure and lipid profiles. Besides glucose control, GLP-1 functions as an enterogastrone, causing a wide range of GI responses. Studies have shown that endogenous GLP-1 and its derived therapies slow down digestion by affecting the stomach, intestines, exocrine pancreas, gallbladder and liver. Understanding the GI actions of GLP-1 based therapies is clinically relevant; because GI side effects are common and need to be recognised, and because these drugs may be used to treat GI disease.

引用

收藏

页码：702 / 711

页数：10

相关论文

共 170 条

[1]

The Extrapancreatic Effects of Glucagon-Like Peptide-1 and Related Peptides [J].

Abu-Hamdah, Rania ;

Rabiee, Atoosa ;

Meneilly, Graydon S. ;

Shannon, Richard P. ;

Andersen, Dana K. ;

Elahi, Dariush .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 94 (06) :1843-1852

[2]

Peripheral motor action of glucagon-like peptide-1 through enteric neuronal receptors [J].

Amato, A. ;

Cinci, L. ;

Rotondo, A. ;

Serio, R. ;

Faussone-Pellegrini, M. S. ;

Vannucchi, M. G. ;

Mule, F. .

NEUROGASTROENTEROLOGY AND MOTILITY, 2010, 22 (06) :664-+

[3]

Exogenous glucagon-like peptide 1 reduces contractions in human colon circular muscle [J].

Amato, Antonella ;

Baldassano, Sara ;

Liotta, Rosa ;

Serio, Rosa ;

Mule, Flavia .

JOURNAL OF ENDOCRINOLOGY, 2014, 221 (01) :29-37

[4]

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study [J].

Armstrong, Matthew James ;

Gaunt, Piers ;

Aithal, Guruprasad P. ;

Barton, Darren ;

Hull, Diana ;

Parker, Richard ;

Hazlehurst, Jonathan M. ;

Guo, Kathy ;

Abouda, George ;

Aldersley, Mark A. ;

Stocken, Deborah ;

Gough, Stephen C. ;

Tomlinson, Jeremy W. ;

Brown, Rachel M. ;

Huebscher, Stefan G. ;

Newsome, Philip N. .

LANCET, 2016, 387 (10019) :679-690

[5]

One year of sitagliptin treatment protects against islet amyloid-associated β-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice [J].

Aston-Mourney, Kathryn ;

Subramanian, Shoba L. ;

Zraika, Sakeneh ;

Samarasekera, Thanya ;

Meier, Daniel T. ;

Goldstein, Lynn C. ;

Hull, Rebecca L. .

AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2013, 305 (04) :E475-E484

[6]

Defining the Role of GLP-1 in the Enteroinsulinar Axis in Type 2 Diabetes Using DPP-4 Inhibition and GLP-1 Receptor Blockade [J].

Aulinger, Benedikt A. ;

Bedorf, Anne ;

Kutscherauer, Gabriele ;

de Heer, Jocelyn ;

Holst, Jens J. ;

Goeke, Burkhard ;

Schirra, Joerg .

DIABETES, 2014, 63 (03) :1079-1092

[7]

Rapid oscillations in plasma glucagon-like peptide-1 (GLP-1) in humans: Cholinergic control of GLP-1 secretion via muscarinic receptors [J].

Balks, HJ ;

Holst, JJ ;

vonzurMuhlen, A ;

Brabant, G .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (03) :786-790

[8]

Dipeptidyl Peptidase 4-Deficient Rats Have Improved Bile Secretory Function in High Fat Diet-Induced Steatosis [J].

Ben Shlomo, Shani ;

Zvibel, Isabel ;

Rabinowich, Liane ;

Goldiner, Ilana ;

Shlomai, Amir ;

Santo, Erwin M. ;

Halpern, Zamir ;

Oren, Ran ;

Fishman, Sigal .

DIGESTIVE DISEASES AND SCIENCES, 2013, 58 (01) :172-178

[9]

Dumping Syndrome: A Review of the Current Concepts of Pathophysiology, Diagnosis, and Treatment [J].

Berg, Patrick ;

McCallum, Richard .

DIGESTIVE DISEASES AND SCIENCES, 2016, 61 (01) :11-18

[10]

GLP-1 analogues: a new therapeutic approach to prevent ductopenia in cholangiopathies? [J].

Beuers, Ulrich ;

Goeke, Burkhard .

GUT, 2009, 58 (07) :902-903

← 1 2 3 4 5 6 7 8 9 10 →